In case of lung adenocarcinoma patients, somatic mutations present in the TK domain of EGFR responds well to TKIs targeting EGFR, but these TKI sensitive mutations in EGFR are very rare in ESCC patients [30, 31]. This evidence concerns the gene EGFR and lung adenocarcinoma.